John Majercak

John Majercak has a strong background in the pharmaceutical and biotechnology industry. John is currently working as the Chief Technology Officer at PineTree Therapeutics Inc since May 2023. Prior to this, from April 2020 to April 2023, they served as the Vice President and Head of Antibody Discovery at Molecular Templates. John'srole involved leading antibody discovery efforts using custom B-cell and Phage platforms and targeted epitope discovery for therapeutic development.

Before Molecular Templates, John worked at Bristol Myers Squibb as an Associate Director from January 2019 to April 2020. In this role, they led the "Molecular Rescue" team, focusing on therapeutic antibody discovery using hybridoma and single B-cell-based approaches. John also utilized Next Generation Sequencing technologies to explore the relationship between sequence, epitope, and therapeutic antibody development.

From February 2017 to January 2019, John served as a Principal Scientist at Johnson & Johnson, specializing in therapeutic antibody discovery and immune response modulation. John led lead generation efforts for antibodies in humanized rodent models and employed in vivo immunization strategies, antibody sequence capture, screening, and characterization.

Prior to Johnson & Johnson, John worked at Boehringer Ingelheim as a Principal Scientist from 2014 to 2017. John led two teams focused on CHO antibody production and High Throughput Sequence recovery from antigen specific B-cells. John'sprimary therapeutic focus was on immune-biologics for cancer.

John started their career at Merck in 2005, where they held various roles. As an Associate Principal Scientist in the In Vitro Pharmacology Department, they focused on target identification, validation, and lead optimization for neurological disorders. John also worked as a Senior Research Biologist in the Alzheimer's Department, where they contributed to the identification of next-generation therapeutics for Alzheimer's disease by studying amyloidogenic processing of APP and novel pathways affecting disease progression.

John's early career involved a Post Doctoral Fellowship at Novartis from 2001 to 2004, focusing on functional genomics and cell-based and in vivo models of neuro-diseases. Overall, they have extensive experience in therapeutic antibody discovery, target identification, and development of biologics for various diseases.

John Majercak obtained a PhD in Biochemistry from Rutgers University.